Superovulation in Mares Using Recombinant Equine Follicle Stimulating Hormone: Ovulation Rates, Embryo Retrieval, and Hormone Profiles

Meyers-Brown, Geraldine; McCue, Patrick M.; Niswender, K. D.; Squires, E.L.; DeLuca, Catherine; Bidstrup, L.A.; Colgin, M.; Famula, Thomas R.; Roser, Janet F.

doi:10.1016/j.jevs.2010.09.007

Cited by 14 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of recombinant equine FSH (reFSH) has been reported to induce follicular growth in cyclic mares [58,59]. A study reviewed in 2013 however determined the efficacy of it in deep anestrous mares to be very successful with ovulation rate of 76.7% in response to FSH treatment followed by human chorionic gonadotropin (hCG) administration [60].…”

Section: Recombinant Equine Fsh (Refsh) and Lh (Relh)mentioning

confidence: 99%

Physiological and Clinical Aspects of the Endocrinology of the Estrous Cycle and Pregnancy in Mares

Satué¹,

Gardón²

2021

Animal Reproduction in Veterinary Medicine

View full text Add to dashboard Cite

The use of advanced reproductive endocrinology can generate important economic benefits for equine breeding farms. Pregnancy in the mare involves considerable endocrine changes, which can be explained in part by the development of different structures such as embryonic vesicles, primary and secondary CL, endometrial cups and development of fetoplacental units. Both the pregnant mare and the fetus adapt to this development with unique mechanisms, such as alterations in the maternal endocrine metabolism and hormonal feedback. Since the ability to produce a viable foal is critical for the broodmare, the maintenance of the gestation implies almost a year of physiological effort. Therefore, the joint knowledge of basic reproductive science and current clinical endocrinology allows veterinarians and breeders to be better positioned to achieve their objectives. This chapter reviews normal and abnormal endocrine patterns during the equine estrual cycle, pregnancy. We also consider hormonal evaluation related to placentitis, abortions, recurrent pregnancy loss, and premature deliveries. Also, several aspects associated with endocrinological control of the reproductive cycle, ovulation, parturition, high-risk mare, and hormone supplementation will be developed.

show abstract

Section: Recombinant Equine Fsh (Refsh) and Lh (Relh)mentioning

confidence: 99%

Physiological and Clinical Aspects of the Endocrinology of the Estrous Cycle and Pregnancy in Mares

Satué¹,

Gardón²

2021

Animal Reproduction in Veterinary Medicine

View full text Add to dashboard Cite

show abstract

“…All these require the development and application of cumbersome purification protocols to concentrate and purify the protein to guarantee the quality of the final product. In this context, production of recombinant hormones appears as an attractive solution to overcome these drawbacks, having reproducible superovulation effects [ 12 ] by using considerably smaller doses than those utilized with animal-derived hormones [ 19 ].…”

Section: Recombinant Hormones In Reproductionmentioning

confidence: 99%

“…In some cases, human embryonic kidney (HEK) cells have been chosen as a cell factory to produce bovine FSH (Nanocore Biotecnologia SA) used to supplement culture medium for in vitro follicle development in mares [ 29 ], dogs [ 30 ], goats, and sheep [ 31 ] (Table 1 ). The equine reproduction research industry has clearly been a user and promoter of this drug to stimulate follicular growth [ 6 , 19 , 32 , 33 ] and ovulation [ 34 ] in mares. Even so, although the human version of this long-acting and single-chain FSH, Elonva (Corifollitropin α; MSD) was already available in 1992 [ 35 – 38 ], the bovine and equine analogs did not reach the market until 2008 [ 6 ].…”

Section: Recombinant Hormones In Reproductionmentioning

confidence: 99%

Trends in recombinant protein use in animal production

et al. 2017

View full text Add to dashboard Cite

Recombinant technologies have made possible the production of a broad catalogue of proteins of interest, including those used for animal production. The most widely studied proteins for the animal sector are those with an important role in reproduction, feed efficiency, and health. Nowadays, mammalian cells and fungi are the preferred choice for recombinant production of hormones for reproductive purposes and fibrolytic enzymes to enhance animal performance, respectively. However, the development of low-cost products is a priority, particularly in livestock. The study of cell factories such as yeast and bacteria has notably increased in the last decades to make the new developed reproductive hormones and fibrolytic enzymes a real alternative to the marketed ones. Important efforts have also been invested to developing new recombinant strategies for prevention and therapy, including passive immunization and modulation of the immune system. This offers the possibility to reduce the use of antibiotics by controlling physiological processes and improve the efficacy of preventing infections. Thus, nowadays different recombinant fibrolytic enzymes, hormones, and therapeutic molecules with optimized properties have been successfully produced through cost-effective processes using microbial cell factories. However, despite the important achievements for reducing protein production expenses, alternative strategies to further reduce these costs are still required. In this context, it is necessary to make a giant leap towards the use of novel strategies, such as nanotechnology, that combined with recombinant technology would make recombinant molecules affordable for animal industry.

show abstract

“…It is certainly true that the potential welfare issues for a donor mare, including those associated with the flushing procedure and with repeat injections to attempt to induce superovulation when used (Meyers‐Brown and others 2010), exceed the potential welfare issues for the recipient mare (in whom non‐surgical transfer differs little from a conventional AI). Overall, ET has greater potential to cause welfare issues than AI.…”

Section: Literature Searchmentioning

confidence: 99%

Welfare in horse breeding

Campbell

Sandøe

2015

Veterinary Record

View full text Add to dashboard Cite

Welfare problems related to the way horses are bred, whether by coitus or by the application of artificial reproduction techniques (ARTs), have been given no discrete consideration within the academic literature. This paper reviews the existing knowledge base about welfare issues in horse breeding and identifies areas in which data is lacking. We suggest that all methods of horse breeding are associated with potential welfare problems, but also that the judicious use of ARTs can sometimes help to address those problems. We discuss how negative welfare effects could be identified and limited and how positive welfare effects associated with breeding might be maximised. Further studies are needed to establish an evidence base about how stressful or painful various breeding procedures are for the animals involved, and what the lifetime welfare implications of ARTs are for future animal generations.

show abstract

Superovulation in Mares Using Recombinant Equine Follicle Stimulating Hormone: Ovulation Rates, Embryo Retrieval, and Hormone Profiles

Cited by 14 publications

References 40 publications

Physiological and Clinical Aspects of the Endocrinology of the Estrous Cycle and Pregnancy in Mares

Physiological and Clinical Aspects of the Endocrinology of the Estrous Cycle and Pregnancy in Mares

Trends in recombinant protein use in animal production

Welfare in horse breeding

Contact Info

Product

Resources

About